All Pharma News
OSE Immunotherapeutics Reports Positive Phase 2 Lusvertikimab Results

OSE Immunotherapeutics Reports Positive Phase 2 Lusvertikimab Results
GLOBENEWSWIRE
24 Jul 2024
Share Share
OSE Reports Symptom Improvements For Ulcerative Colitis Drug

OSE Reports Symptom Improvements For Ulcerative Colitis Drug
FIERCE BIOTECH
24 Jul 2024
Share Share
Boehringer and OSE to advance cancer immunotherapy to clinics

Boehringer and OSE to advance cancer immunotherapy to clinics
PHARMACEUTICAL TECHNOLOGY
04 Jul 2024
Share Share
OSE Announces Publication of Preclinical Results with Lusvertikimab in Leukemia

OSE Announces Publication of Preclinical Results with Lusvertikimab in Leukemia
GLOBENEWSWIRE
01 Jul 2024
Share Share
OSE Immunotherapeutics Enters Agreement With MSK For CAR T-Cell Therapies

OSE Immunotherapeutics Enters Agreement With MSK For CAR T-Cell Therapies
PHARMABIZ
25 Jun 2024
Share Share
OSE announces CAR T-cell therapy commercial and revenue sharing agreement.

OSE announces CAR T-cell therapy commercial and revenue sharing agreement.
GLOBENEWSWIRE
24 Jun 2024
Share Share
OSE Immunotherapeutics Presents MRNA Platform Data At FOCIS Annual Meeting

OSE Immunotherapeutics Presents MRNA Platform Data At FOCIS Annual Meeting
GLOBENEWSWIRE
20 Jun 2024
Share Share
OSE Immunotherapeutics Reports On 2024 Meeting And Board Evolution

OSE Immunotherapeutics Reports On 2024 Meeting And Board Evolution
GLOBENEWSWIRE
19 Jun 2024
Share Share
OSE, Nantes: Positive Renal Transplant Immunotherapy Data

OSE, Nantes: Positive Renal Transplant Immunotherapy Data
GLOBENEWSWIRE
05 Jun 2024
Share Share
OSE Immunotherapeutics Provides Business and Corporate Update

OSE Immunotherapeutics Provides Business and Corporate Update
GLOBENEWSWIRE
30 May 2024
Share Share